NO20054260L - Disepergebar formulering av en anti-inflammatorisk forbindelse - Google Patents

Disepergebar formulering av en anti-inflammatorisk forbindelse

Info

Publication number
NO20054260L
NO20054260L NO20054260A NO20054260A NO20054260L NO 20054260 L NO20054260 L NO 20054260L NO 20054260 A NO20054260 A NO 20054260A NO 20054260 A NO20054260 A NO 20054260A NO 20054260 L NO20054260 L NO 20054260L
Authority
NO
Norway
Prior art keywords
inflammatory compound
inflammatory agent
dispersible
dispersible formulation
inflammatory
Prior art date
Application number
NO20054260A
Other languages
English (en)
Other versions
NO20054260D0 (no
Inventor
Niki Ann Waldron
Nancy Jean Britten
John W Burns
John W Hallberg
Jeffrey L Watts
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Publication of NO20054260D0 publication Critical patent/NO20054260D0/no
Publication of NO20054260L publication Critical patent/NO20054260L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0041—Mammary glands, e.g. breasts, udder; Intramammary administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0046—Ear
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Dispersion Chemistry (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Det beskrives en fremgangsmåte for behandling av en inflammatorisk tilstand i et væskeholdig organ som har en naturlig utløpsåpning, så som juret til et melkeproduserende dyr, eller et øre. Fremgangsmåten omfatter administrering til organet via utløpsåpningen, av en farmasøytisk blanding som omfatter et antiinflammatorisk middel og en bærer som omfatter en amfipatisk olje som er vanndispergerbar og uløselig i etanol, mikrokrystallinsk voks og en farmasøytisk akseptabel ikke-vandig bærer. Dessuten tilveiebringes en slik blanding som omfatter det antiinflammatoriske middel. Blandingen er lett dispergerbar i væsken i det væskeholdige organ.
NO20054260A 2003-03-20 2005-09-15 Disepergebar formulering av en anti-inflammatorisk forbindelse NO20054260L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45632503P 2003-03-20 2003-03-20
PCT/IB2004/000826 WO2004082588A2 (en) 2003-03-20 2004-03-10 Dispersible formulation of an anti-inflammatory agent

Publications (2)

Publication Number Publication Date
NO20054260D0 NO20054260D0 (no) 2005-09-15
NO20054260L true NO20054260L (no) 2005-12-12

Family

ID=33030094

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20054260A NO20054260L (no) 2003-03-20 2005-09-15 Disepergebar formulering av en anti-inflammatorisk forbindelse

Country Status (26)

Country Link
US (1) US20040235803A1 (no)
EP (1) EP1608407B1 (no)
JP (1) JP2006520779A (no)
KR (1) KR100717433B1 (no)
CN (1) CN1761487A (no)
AR (1) AR043650A1 (no)
AT (1) ATE337793T1 (no)
AU (1) AU2004222523A1 (no)
BR (1) BRPI0408556A (no)
CA (1) CA2519125A1 (no)
CL (1) CL2004000573A1 (no)
CO (1) CO5611169A2 (no)
CY (1) CY1105652T1 (no)
DE (1) DE602004002201T2 (no)
DK (1) DK1608407T3 (no)
ES (1) ES2270361T3 (no)
MX (1) MXPA05009978A (no)
NO (1) NO20054260L (no)
PL (1) PL1608407T3 (no)
PT (1) PT1608407E (no)
RU (1) RU2325189C2 (no)
SI (1) SI1608407T1 (no)
TW (1) TWI262084B (no)
UY (1) UY28235A1 (no)
WO (1) WO2004082588A2 (no)
ZA (1) ZA200506920B (no)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7858115B2 (en) * 2004-06-24 2010-12-28 Idexx Laboratories Phospholipid gel compositions for drug delivery and methods of treating conditions using same
US7854943B2 (en) * 2004-06-24 2010-12-21 Idexx Laboratories Phospholipid gel compositions for drug delivery and methods of treating conditions using same
US7618651B2 (en) * 2004-06-24 2009-11-17 Idexx Laboratories Pharmaceutical compositions for drug delivery and methods of treating or preventing conditions using same
US20070099883A1 (en) * 2005-10-07 2007-05-03 Cheryl Lynn Calis Anhydrous mometasone furoate formulation
WO2010036427A1 (en) 2008-06-17 2010-04-01 Brigham Young University Cationic steroid antimicrobial diagnostic, detection, screening and imaging methods
GB2477590A (en) * 2010-02-05 2011-08-10 Biocopea Ltd A non-steroidal anti-inflammatory drug (NSAID) formulation comprising a lipid carrier
TR201002473A2 (tr) * 2010-03-31 2011-09-21 Mustafa Nevzat �La� Sanay�� A.�. Herpes zoster hastalığının bır opiat reseptör antagonist kullanılarak tedavi yöntemi.
US8968755B2 (en) 2010-10-23 2015-03-03 Joel Schlessinger Topical base and active agent-containing compositions, and methods for improving and treating skin
US8685381B2 (en) 2010-10-23 2014-04-01 Joel Schlessinger Topical base and active agent-containing compositions, and methods for improving and treating skin
US10695431B2 (en) 2010-10-29 2020-06-30 Infirst Healthcare Limited Solid solution compositions and use in cardiovascular disease
US11224659B2 (en) 2010-10-29 2022-01-18 Infirst Healthcare Limited Solid solution compositions and use in severe pain
US11730709B2 (en) 2010-10-29 2023-08-22 Infirst Healthcare Limited Compositions and methods for treating severe pain
US8895537B2 (en) 2010-10-29 2014-11-25 Infirst Healthcare Ltd. Compositions and methods for treating cardiovascular diseases
US11202831B2 (en) 2010-10-29 2021-12-21 Infirst Healthcare Limited Solid solution compositions and use in cardiovascular disease
US10695432B2 (en) 2010-10-29 2020-06-30 Infirst Healthcare Limited Solid solution compositions and use in severe pain
US9504664B2 (en) 2010-10-29 2016-11-29 Infirst Healthcare Limited Compositions and methods for treating severe pain
US9744132B2 (en) 2010-10-29 2017-08-29 Infirst Healthcare Limited Solid solution compositions and use in chronic inflammation
US9308213B2 (en) 2010-10-29 2016-04-12 Infirst Healthcare Limited Solid solution compositions and use in chronic inflammation
US9271950B2 (en) 2010-10-29 2016-03-01 Infirst Healthcare Limited Compositions for treating chronic inflammation and inflammatory diseases
US9737500B2 (en) 2010-10-29 2017-08-22 Infirst Healthcare Limited Compositions and methods for treating severe pain
GB201020032D0 (en) * 2010-11-25 2011-01-12 Sigmoid Pharma Ltd Composition
CA2842460C (en) 2011-07-20 2019-08-20 Brigham Young University Hydrophobic ceragenin compounds and devices incorporating same
US9603859B2 (en) 2011-09-13 2017-03-28 Brigham Young University Methods and products for increasing the rate of healing of tissue wounds
US9694019B2 (en) 2011-09-13 2017-07-04 Brigham Young University Compositions and methods for treating bone diseases and broken bones
RU2625838C2 (ru) 2011-12-21 2017-07-19 Брихэм Янг Юниверсити Композиции для ухода за полостью рта
US9533063B1 (en) 2012-03-01 2017-01-03 Brigham Young University Aerosols incorporating ceragenin compounds and methods of use thereof
WO2013165574A2 (en) 2012-05-02 2013-11-07 Brigham Young University Ceragenin particulate materials and methods for making same
RU2486905C1 (ru) * 2012-05-28 2013-07-10 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Кубанский государственный технологический университет" (ФГБОУ ВПО "КубГТУ") Средство для лечения мастита у животных
WO2014062960A1 (en) * 2012-10-17 2014-04-24 Brigham Young University Treatment and prevention of mastitis
CN105451742B (zh) 2013-01-07 2021-04-06 布莱阿姆青年大学 减少细胞增殖和治疗某些疾病的方法
CN113559264A (zh) * 2013-02-08 2021-10-29 罗达制药公司 治疗包括***炎的微生物感染的方法
US10568893B2 (en) 2013-03-15 2020-02-25 Brigham Young University Methods for treating inflammation, autoimmune disorders and pain
US11524015B2 (en) 2013-03-15 2022-12-13 Brigham Young University Methods for treating inflammation, autoimmune disorders and pain
WO2014151411A1 (en) 2013-03-15 2014-09-25 Brigham Young University Methods for treating inflammation, autoimmune disorders and pain
US9387215B2 (en) 2013-04-22 2016-07-12 Brigham Young University Animal feed including cationic cholesterol additive and related methods
JP6539274B2 (ja) 2013-08-12 2019-07-03 ファーマシューティカル マニュファクチュアリング リサーチ サービシズ，インコーポレーテッド 押出成形された即放性乱用抑止性丸剤
US11690855B2 (en) 2013-10-17 2023-07-04 Brigham Young University Methods for treating lung infections and inflammation
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
WO2015138032A2 (en) 2013-12-20 2015-09-17 President And Fellows Of Harvard College Organomimetic devices and methods of use and manufacturing thereof
US20150203527A1 (en) 2014-01-23 2015-07-23 Brigham Young University Cationic steroidal antimicrobials
CA2844321C (en) 2014-02-27 2021-03-16 Brigham Young University Cationic steroidal antimicrobial compounds
US9867836B2 (en) 2014-03-13 2018-01-16 Brigham Young University Lavage and/or infusion using CSA compounds for increasing fertility in a mammal
US10220045B2 (en) 2014-03-13 2019-03-05 Brigham Young University Compositions and methods for forming stabilized compositions with reduced CSA agglomeration
US9931350B2 (en) 2014-03-14 2018-04-03 Brigham Young University Anti-infective and osteogenic compositions and methods of use
US9686966B2 (en) 2014-04-30 2017-06-27 Brigham Young University Methods and apparatus for cleaning or disinfecting a water delivery system
US10441595B2 (en) 2014-06-26 2019-10-15 Brigham Young University Methods for treating fungal infections
US10238665B2 (en) 2014-06-26 2019-03-26 Brigham Young University Methods for treating fungal infections
AU2015290098B2 (en) 2014-07-17 2018-11-01 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
RU2557691C1 (ru) * 2014-07-25 2015-07-27 Государственное бюджетное учреждение здравоохранения города Москвы "Московский научно-практический Центр оториноларингологии им Л.И. Свержевского" Департамента здравоохранения города Москвы Способ определения длительности лечения активных форм отосклероза
US10227376B2 (en) 2014-08-22 2019-03-12 Brigham Young University Radiolabeled cationic steroid antimicrobials and diagnostic methods
US10155788B2 (en) 2014-10-07 2018-12-18 Brigham Young University Cationic steroidal antimicrobial prodrug compositions and uses thereof
AU2015336065A1 (en) 2014-10-20 2017-05-04 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
CN104688554A (zh) * 2015-01-30 2015-06-10 柳州两面针股份有限公司 水杨苷在制备口腔护理保健品中的应用
US9527883B2 (en) 2015-04-22 2016-12-27 Brigham Young University Methods for the synthesis of ceragenins
US10370403B2 (en) 2015-04-22 2019-08-06 Brigham Young University Methods for the synthesis of ceragenins
US9434759B1 (en) 2015-05-18 2016-09-06 Brigham Young University Cationic steroidal antimicrobial compounds and methods of manufacturing such compounds
KR101625020B1 (ko) 2016-02-11 2016-06-01 최예도 식기세척기
US10226550B2 (en) 2016-03-11 2019-03-12 Brigham Young University Cationic steroidal antimicrobial compositions for the treatment of dermal tissue
US10959433B2 (en) 2017-03-21 2021-03-30 Brigham Young University Use of cationic steroidal antimicrobials for sporicidal activity
JP6802946B2 (ja) * 2017-09-08 2020-12-23 ドン クック ファーム カンパニー リミテッドＤｏｎｇ Ｋｏｏｋ Ｐｈａｒｍ Ｃｏ．，Ｌｔｄ 難聴の予防または処置のための活性成分としてアボカド油画分を含有する医薬組成物
EP3603645A1 (en) 2018-07-30 2020-02-05 Virbac Novel use of glucocorticoids for the treatment of epithelial microbial infections of a fluid containing organ with a natural exterior orifice in mammals

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3636194A (en) * 1969-10-23 1972-01-18 Douglas G Parizeau Composition and method for treating mastitis with therapeutic agents
DE2063896A1 (de) * 1970-12-28 1972-07-20 Dynamit Nobel Ag, 5210 Troisdorf Salbengrundlagen auf der Basis von Triglyceriden gesättigter mittelkettiger Fettsäuren und Verfahren zu deren Herstellung
US4299501A (en) * 1979-08-10 1981-11-10 Ortho Pharmaceutical Corporation Continuous process for the preparation of semisolid dispersions
ES2079994B1 (es) * 1992-10-07 1996-08-01 Cusi Lab Formulacion farmaceutica a base de polimixina-trimetoprim y un agente antiinflamatorio para su utilizacion topica oftalmica y otica.
US5474995A (en) * 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
US5466823A (en) * 1993-11-30 1995-11-14 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides
US5633272A (en) * 1995-02-13 1997-05-27 Talley; John J. Substituted isoxazoles for the treatment of inflammation
ES2182991T3 (es) * 1995-05-25 2003-03-16 Searle & Co Metodo para la preparar 3-haloalquil-1h-pirazoles.
ATE214931T1 (de) * 1995-06-06 2002-04-15 Bayer Ag Antibakterielle präparate für die ohren ohne irritierende, sensibilisierende und ototoxische wirkungen
US5756529A (en) * 1995-09-29 1998-05-26 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides for use in veterinary therapies
AP9700912A0 (en) * 1996-01-11 1997-01-31 Smithkline Beecham Corp Novel cycloalkyl substituted imidazoles
EE03685B1 (et) * 1996-04-12 2002-04-15 G.D. Searle & Co. Asendatud benseensulfoonamiidi derivaadid kui COX-2 inhibiitorite eelravimid
US5736151A (en) * 1996-12-09 1998-04-07 Pharmacia & Upjohn Company Antibiotic oil suspensions
US6307047B1 (en) * 1997-08-22 2001-10-23 Abbott Laboratories Prostaglandin endoperoxide H synthase biosynthesis inhibitors
US6440964B1 (en) * 1998-09-30 2002-08-27 Alcon Manufacturing, Ltd. Compositions and methods for treating ophthalmic and otic infections
AR020660A1 (es) * 1998-09-30 2002-05-22 Alcon Lab Inc Composiciones antibioticas para el tratamiento de ojos, oidos y nariz
US6509327B1 (en) * 1998-09-30 2003-01-21 Alcon Manufacturing, Ltd. Compositions and methods for treating otic, ophthalmic and nasal infections
US6395746B1 (en) * 1998-09-30 2002-05-28 Alcon Manufacturing, Ltd. Methods of treating ophthalmic, otic and nasal infections and attendant inflammation
US7064132B2 (en) * 1999-11-28 2006-06-20 Scientific Development And Research, Inc. Composition and method for treatment of otitis external
US6676930B2 (en) * 1999-11-28 2004-01-13 Scientific Development And Research, Inc. Composition and method for treatment of otitis media
NZ519781A (en) * 1999-12-23 2004-04-30 Nitromed Inc Nitrosated and nitrosylated cyclooxygenase-2 inhibitors, compositions and methods of use
US20010049366A1 (en) * 2000-02-09 2001-12-06 Alcon Universal Ltd. Topical solution formulations containing an antibiotic and a corticosteroid
AU2001251011A1 (en) * 2000-03-27 2001-10-08 The General Hospital Corporation Treatments for immune-mediated ear disorders
WO2001087328A2 (en) * 2000-05-12 2001-11-22 Immunex Corporation Interleukin-1 inhibitors in the treatment of diseases
WO2001094369A2 (en) * 2000-06-08 2001-12-13 The University Of Texas System Heterocycle derivatives and methods of use for treating anthrax infection
EP1301500B1 (en) * 2000-06-22 2007-11-21 Nitromed, Inc. Nitrosated and nitrosylated taxanes, compositions and methods of use

Also Published As

Publication number Publication date
PT1608407E (pt) 2006-12-29
MXPA05009978A (es) 2005-11-04
ZA200506920B (en) 2007-09-26
CN1761487A (zh) 2006-04-19
TW200503756A (en) 2005-02-01
SI1608407T1 (sl) 2006-12-31
RU2325189C2 (ru) 2008-05-27
KR20050114249A (ko) 2005-12-05
DE602004002201T2 (de) 2007-09-20
JP2006520779A (ja) 2006-09-14
BRPI0408556A (pt) 2006-03-21
WO2004082588A3 (en) 2004-12-23
UY28235A1 (es) 2004-11-08
RU2005129266A (ru) 2006-03-20
DK1608407T3 (da) 2006-12-04
KR100717433B1 (ko) 2007-05-14
AR043650A1 (es) 2005-08-03
EP1608407B1 (en) 2006-08-30
DE602004002201D1 (de) 2006-10-12
WO2004082588A2 (en) 2004-09-30
US20040235803A1 (en) 2004-11-25
CA2519125A1 (en) 2004-09-30
AU2004222523A1 (en) 2004-09-30
ES2270361T3 (es) 2007-04-01
TWI262084B (en) 2006-09-21
ATE337793T1 (de) 2006-09-15
CY1105652T1 (el) 2010-12-22
NO20054260D0 (no) 2005-09-15
CL2004000573A1 (es) 2005-01-14
EP1608407A2 (en) 2005-12-28
PL1608407T3 (pl) 2006-12-29
CO5611169A2 (es) 2006-02-28

Similar Documents

Publication Publication Date Title
NO20054260L (no) Disepergebar formulering av en anti-inflammatorisk forbindelse
NO20054777L (no) Dispergerbar farmasoytisk sammesetning for behandling av mastitt og/eller otittforstyrrelser
NO20052306L (no) Dispergerbare farmasoytiske blandinger.
CN114206312A (zh) 用于治疗炎性皮肤病的局部组合物和方法
NO20060982L (no) Dispergerende formulering for et anti-inflammatorisk middel
RU2408372C2 (ru) Применение октенидина дигидрохлорида в полутвердых препаратах
NO20075660L (no) Blanding for behandling av inflammatoriske sykdommer
RS51961B (en) APPLICATION OF FLIBANSERINE FOR TREATMENT OF SEXUAL DESIRE DISORDERS IN PREMENOPAUSE
JP6456533B2 (ja) ロキソプロフェン含有外用剤組成物
WO2002067988A3 (en) Use of natural egfr inhibitors to prevent side effects due to retinoid therapy, soaps, and other stimuli that activate the epidermal growth receptor
EP2124922B1 (en) Composition comprising rutin and polyunsaturated fatty acid having an inhibitory activity on 5 alpha-reductase
HUP0104718A2 (hu) Mikronizált eplerenon kompozíciók és eljárás az előállításukra
NO20071354L (no) anvendelse av samme Butylftalid selvemulsifiserene medikamentavgivelsessystem, samt fremgangsmater for fremstilling og anvendelse av samme.
CN100577144C (zh) 用于预防和治疗痤疮的局部制剂
de Oliveira Azevedo et al. Antinociceptive and anti-inflammatory effects of myricetin 3-O-β-galactoside isolated from Davilla elliptica: involvement of the nitrergic system
KR20050033671A (ko) 손톱용 항진균 외용제
MXPA04007082A (es) Composiciones topicas que tienen un ingrediente natural y metodo de uso.
JP2008069109A (ja) 外用医薬組成物
WO2013133062A1 (ja) アレルギー性鼻炎用塗付剤
JP2015110557A (ja) ロキソプロフェンを配合する外用剤組成物
JP6253495B2 (ja) ロキソプロフェンを含有する外用剤組成物
US20100010078A1 (en) Methods of treating androgen dependent prostate cancer by administering an active pharmaceutical ingredient being fisetin, 3,3',4',7-tetrahydroxyflavone or a derivative thereof, in an oral, transdermal or topical dosage form
KR101270929B1 (ko) 섬오갈피 근피 성분인 아칸토산을 이용한 피부 미백제 조성물
NO20061354L (no) Fremgangsmater og sammensetninger for oral administrering av prodroger av protonpumpe inhibitatorer
BR112020018138A2 (pt) Composições e métodos para tratar fibrose cutânea

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application